Trametinib (GSK1120212) is an oral drug that selectively targets MEK1/2 and has been approved by US Food and Drug Administration for the treatment of metastatic melanoma (Dummer et al., 2020). This evidence concerns the gene MAP2K1 and metastatic melanoma.